The day pharma’s weight-loss gold rush intensified

Lilly’s quarterly results Thursday, combined with Novo Nordisk’s unsolicited offer for a startup, confirm the $72 billion ...

‘I can't shake the anxiety about weight regain if I'm priced out of Mounjaro’: On life after GLP-1s

One writer felt she'd finally reached her bodily happy ever after via GLP-1 jabs. But with soaring prices and scientific unknowns on the horizon...now what?

Eli Lilly says weight-loss pill a candidate for speedy approval under new US program

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...
EconoTimes

Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand

Eli Lilly announced that its experimental weight-loss pill, orforglipron, meets most of the criteria for the U.S. Food and ...

Eli Lilly Boosts Its Outlook on High Demand for Popular Weight-Loss Drugs

Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro.  The company also ...

Eli Lilly’s obesity and diabetes treatments fuel growth and spark bidding war

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...
Axios on MSN

Weight-loss drug wars enter new phase as Lilly goes global

Eli Lilly's GLP-1 sales are rising at an unexpectedly strong pace, prompting its arch rival to make a surprising bid for an ...